Further analysis was performed to compare plasma anti-HER2 IgG levels between subgroups and indicated that anti-HER2 IgG levels were slightly lower in patients with oral benign tumor and early stage OSCC than control subjects, while plasma anti-HER2 IgG levels showed a trend toward an increase in OSCC patients at the middle & advanced stages compared with those at the early stage ( Table 2 ).
← all excerpts
Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma.
1
—
—